跳转至内容
Merck

F5055

Sigma-Aldrich

FGFR1 (FLT2) (399-822), active, GST tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

别名:

BFGFR, C-FGR, CD331, CEK, FLG, FLT2, KAL2, N-SAM

登录查看公司和协议定价


About This Item

分類程式碼代碼:
51111800
NACRES:
NA.32

重組細胞

expressed in baculovirus infected Sf9 cells

品質等級

產品線

PRECISIO® Kinase

化驗

≥70% (SDS-PAGE)

形狀

buffered aqueous glycerol solution

比活性

150-204 nmol/min·mg

分子量

~73 kDa

UniProt登錄號

運輸包裝

dry ice

儲存溫度

−70°C

基因資訊

human ... FGFR1(2260)

一般說明

FGFR1 (fibroblast growth factor receptor 1) is one of the four variants of FGFR, the ligand of which are the FGF polypeptides. FGFRs are highly conserved in nature, and the variants differ in their intracellular kinase and extracellular ligand-binding domains. It is a receptor tyrosine kinase localized to the human chromosome 8p12.

生化/生理作用

Studies in genetically modified mice show that the epithelial-stromal interaction mediated by FGFR1 and FGF are responsible for the pathophysiology of prostate cancer. The antitumor property of dovitinib is mediated by the inhibition of FGFR1 signaling in prostate cancer to prevent bone metastasis. In malignant pleural mesothelioma (MPM), FGFR1 mRNA levels are elevated, though the gene is not amplified. FGFR1 autocrine signaling is implicated in the tumorigenesis of MPM, and thus, FGFR1 pathway has potential as a therapeutic target in the same. This gene is amplified in squamous cell lung cancer, head and neck squamous cell cancer (HNSCC) and breast cancer.

外觀

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

法律資訊

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Casper Groth et al.
The International journal of developmental biology, 46(4), 393-400 (2002-07-27)
The vertebrate fibroblast growth factor receptor 1 (FGFR1) is alternatively spliced generating multiple splice variants that are differentially expressed during embryo development and in the adult body. The restricted expression patterns of FGFR1 isoforms, together with differential expression and binding
M Fernanda Amary et al.
Cancer medicine, 3(4), 980-987 (2014-05-28)
Osteosarcoma, the most common primary bone sarcoma, is a genetically complex disease with no widely accepted biomarker to allow stratification of patients for treatment. After a recent report of one osteosarcoma cell line and one tumor exhibiting fibroblastic growth factor
Xinhai Wan et al.
Science translational medicine, 6(252), 252ra122-252ra122 (2014-09-05)
Bone is the most common site of prostate cancer (PCa) progression to a therapy-resistant, lethal phenotype. We found that blockade of fibroblast growth factor receptors (FGFRs) with the receptor tyrosine kinase inhibitor dovitinib has clinical activity in a subset of
X Xu et al.
Cell and tissue research, 296(1), 33-43 (1999-04-13)
Fibroblast growth factor (FGF) receptors constitute a family of four membrane-spanning tyrosine kinases (FGFR1-4) which serve as high-affinity receptors for 17 growth factors (FGF1-17). To study functions of FGF/ FGFR signals in development, mice that carry mutations in each receptor
Lindsay A Marek et al.
Molecular cancer research : MCR, 12(10), 1460-1469 (2014-06-27)
Malignant pleural mesothelioma (MPM) is associated with asbestos exposure and is a cancer that has not been significantly affected by small molecule-based targeted therapeutics. Previously, we demonstrated the existence of functional subsets of lung cancer and head and neck squamous

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门